文献速递临床试验与 GCP

艾司氯胺酮联合普瑞巴林对脊髓肿瘤切除术患者急性术后疼痛的影响:随机对照试验研究方案

Esketamine combined with pregabalin on acute postoperative pain in patients undergoing resection of spinal neoplasms: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2023-02-25

这是一项随机双盲对照试验方案,评估艾司氯胺酮联合普瑞巴林对脊髓肿瘤切除术患者术后疼痛的影响。18至65岁拟行脊髓肿瘤切除术的患者按1:1随机分为联合组和对照组,联合组术中至术后48小时给予艾司氯胺酮、术前2小时至术后2周口服普瑞巴林,对照组给予生理盐水和安慰剂胶囊,两组均使用患者自控静脉镇痛作为背景镇痛。主要结局为术后48小时内发生急性中重度术后疼痛(VAS≥40)的患者比例。

要点

  • 拟纳入18至65岁脊髓肿瘤切除术患者,1:1随机分为艾司氯胺酮联合普瑞巴林组与对照组。
  • 联合组艾司氯胺酮术中至术后48小时给药,普瑞巴林术前2小时至术后2周给药。
  • 主要结局为术后48小时内急性中重度术后疼痛(VAS≥40,范围0-100)的患者比例。

核心结论

  • 本试验旨在评估艾司氯胺酮联合普瑞巴林对脊髓肿瘤切除术患者急性术后疼痛的效果,并将考察该围术期疼痛管理策略的安全性。

研究设计与样本

  • 随机双盲对照试验方案,拟纳入18至65岁拟行脊髓肿瘤切除术的患者,按1:1比例随机分配至联合组和对照组。
  • 联合组术中至术后48小时给予艾司氯胺酮,术前2小时至术后2周口服普瑞巴林;对照组在相同时间点给予生理盐水和安慰剂胶囊。
  • 两组均接受患者自控静脉镇痛作为背景镇痛方案(含舒芬太尼100 μg和昂丹司琼16 mg),持续至术后2天。
  • 所有研究者和患者均设盲至研究完成。

主要发现

  • 主要结局为术后48小时内发生急性中重度术后疼痛(视觉模拟量表VAS≥40,范围0-100,0为无痛、100为最剧烈疼痛)的患者比例。
  • 次要结局包括离开手术室后0-2小时、2-24小时、24-48小时、48-72小时及出院前24小时的最大VAS评分(患者在接受访视前过去24小时内感到最剧烈疼痛时)。
  • 次要结局还包括各其他时间点急性中重度术后疼痛的发生率、慢性术后疼痛评估、神经病理性疼痛评估,以及药物相关不良事件和其他术后并发症(如术后谵妄和术后恶心呕吐)的发生率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Perioperative pain management is one of the most challenging issues for patients with spinal neoplasms. Inadequate postoperative analgesia usually leads to severe postsurgical pain, which could cause patients to suffer from many other related complications. Meanwhile, there is no appropriate analgesic strategy for patients with spinal neoplasms. METHODS/DESIGN: This is a protocol for a randomized double-blind controlled trial to evaluate the effect of esketamine combined with pregabalin on postsurgical pain in spinal surgery. Patients aged 18 to 65 years scheduled for spinal neoplasm resection will be randomly allocated into the combined and control groups in a 1:1 ratio. In the combined group, esketamine will be given during the during the surgery procedure until 48-h postoperative period, and pregabalin will be taken from 2 h before the surgery to 2 weeks postoperatively. The control group will receive normal saline and placebo capsules at the same time points. Both groups received a background analgesic regimen by using patient-controlled intravenous analgesia (containing 100 μg sufentanil and 16 mg ondansetron) until 2 days after surgery. To ensure the accuracy and reliability of this trial, all the researchers and patients will be blinded until the completion of this study. The primary outcome will be the proportion of patients with acute moderate-to-severe postsurgical pain (visual analog scale, VAS ≥ 40, range: 0-100, with 0, no pain; 100, the worst pain) during the 48-h postoperative period. The secondary outcomes will include the maximal VAS scores (when the patients felt the most intense pain over the last 24 h before being interviewed) at 0-2 h, 2-24 h, 24-48 h, and 48-72 h after leaving the operating room and 24 h before discharge; the incidence of acute moderate-to-severe postsurgical pain at each other time point; chronic postsurgical pain assessment; neuropathic pain assessment; and the incidence of drug-related adverse events and other postoperative complications, such as postoperative delirium and postoperative nausea and vomiting (PONV). DISCUSSION: The aim of this study was to evaluate the effect of esketamine combined with pregabalin on acute postsurgical pain in patients undergoing resection of spinal neoplasms. The safety of this perioperative pain management strategy will also be examined. TRIAL REGISTRATION: ClinicalTrials.gov NCT05096468. Registered on October 27, 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Sun W, Wang J, Wang J, et al. Esketamine combined with pregabalin on acute postoperative pain in patients undergoing resection of spinal neoplasms: study protocol for a randomized controlled trial. Trials. 2023. PMID: 36841794. doi:10.1186/s13063-023-07178-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。